Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLK4 is a member of the CDC2-like protein kinase (CLK) family, which are dual specificity kinases capable of phosphorylating both serine/threonine and tyrosine residues. This protein plays a role in the regulation of RNA splicing by phosphorylating serine- and arginine-rich (SR) proteins. Recent studies have linked CLK4 to the regulation of cardiac hypertrophy through phosphorylation of nexilin (NEXN), suggesting it as a potential therapeutic target for heart failure.
Inhibition of CLK4 kinase activity to modulate SR protein phosphorylation and RNA splicing; modulation of NEXN phosphorylation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDC-like kinase 4 (CLK4).